Logo-apb
Adv Pharm Bull. 2015;5(2): 261-267. doi: 10.15171/apb.2015.036
PMID: 26236666        PMCID: PMC4517085

Original Research

Increased P-35, EBI3 Transcripts and Other Treg Markers in Peripheral Blood Mononuclear Cells of Breast Cancer Patients with Different clinical Stages

Maryam Hamidinia 1,2, Mehri Ghafourian Boroujerdnia 1, Abdolhassan Talaiezadeh 2,3, Ghasem Solgi 4, Reyhaneh Roshani 1,2, Sara Iranprast 1,2, Ali Khodadadi 1,2 *

Cited by CrossRef: 18


1- Abdellateif M, Shaarawy S, Kandeel E, El‑Habashy A, Salem M, El‑Houseini M. A novel potential effective strategy for enhancing the antitumor immune response in breast cancer patients using a viable cancer cell‑dendritic cell‑based vaccine. Oncol Lett. 2018; [Crossref]
2- Lisovska N. Multilevel mechanism of immune checkpoint inhibitor action in solid tumors: History, present issues and future development (Review). Oncol Lett. 2022;23(6) [Crossref]
3- Mengmeng Z, Jiacui S, Shanshan D, Yuan Z, Ying Z, Qiuhong L, Dong W, Hui-Ping L. Serum IL-35 Levels Are Associated With Activity and Progression of Sarcoidosis. Front Immunol. 2020;11 [Crossref]
4- He Q, Jamalpour M, Bergquist E, Anderson R, Gustafsson K, Welsh M. Mouse Breast Carcinoma Monocytic/Macrophagic Myeloid-Derived Suppressor Cell Infiltration as a Consequence of Endothelial Dysfunction in Shb-Deficient Endothelial Cells Increases Tumor Lung Metastasis. IJMS. 2021;22(21):11478 [Crossref]
5- Chen X, Shao Q, Hao S, Zhao Z, Wang Y, Guo X, He Y, Gao W, Mao H. CTLA-4 positive breast cancer cells suppress dendritic cells maturation and function. Oncotarget. 2017;8(8):13703 [Crossref]
6- Majidinia M, Yousefi B. DNA repair and damage pathways in breast cancer development and therapy. DNA Repair. 2017;54:22 [Crossref]
7- Naz A, Aslam M, Khan A, Rasul S, Manzoor H, Iqbal R, Shehzad A, Ali M. Genetic polymorphism in association with susceptibility to tuberculosis: a study in a Pakistani population. Braz J Microbiol. 2019;50(2):429 [Crossref]
8- Yi P, Yu W, Xiong Y, Dong Y, Huang Q, Lin Y, Du Y, Hua F. IL-35: New Target for Immunotherapy Targeting the Tumor Microenvironment. 2024;23(2):148 [Crossref]
9- Teymouri M, Pirro M, Fallarino F, Gargaro M, Sahebkar A. IL‐35, a hallmark of immune‐regulation in cancer progression, chronic infections and inflammatory diseases. Intl Journal of Cancer. 2018;143(9):2105 [Crossref]
10- Li X, Singh K, Luo Z, Mejia-Cordova M, Jamalpour M, Lindahl B, Zhang G, Sandler S, Welsh M. Pro-tumoral immune cell alterations in wild type and Shb-deficient mice in response to 4T1 breast carcinomas. Oncotarget. 2018;9(27):18720 [Crossref]
11- Wu W, Jiang H, Li Y, Yan M. IL-35 expression is increased in laryngeal squamous cell carcinoma and in the peripheral blood of patients. 2017;13(5):3303 [Crossref]
12- Yazdani Z, Rafiei A, Golpour M, Zafari P, Moonesi M, Ghaffari S. IL‐35, a double‐edged sword in cancer. J of Cellular Biochemistry. 2020;121(3):2064 [Crossref]
13- Hashemi V, Maleki L, Esmaily M, Masjedi A, Ghalamfarsa G, Namdar A, Yousefi M, Yousefi B, Jadidi-Niaragh F. Regulatory T cells in breast cancer as a potent anti-cancer therapeutic target. International Immunopharmacology. 2020;78:106087 [Crossref]
14- Zhao Z, Chen X, Hao S, Jia R, Wang N, Chen S, Li M, Wang C, Mao H. Increased interleukin-35 expression in tumor-infiltrating lymphocytes correlates with poor prognosis in patients with breast cancer. Cytokine. 2017;89:76 [Crossref]
15- Lisovska N, Shanazarov N. Tumor progression mechanisms: Insights from the central immune regulation of tissue homeostasis (Review). Oncol Lett. 2019; [Crossref]
16- BAYKAL A, TURNA Ö. Current invasive and non-invasive biomarkers in canine mammary tumors. 2021;5(1):39 [Crossref]
17- Akcan U, Karabulut S, İsmail Küçükali C, Çakır S, Tüzün E. Bipolar disorder patients display reduced serum complement levels and elevated peripheral blood complement expression levels. Acta Neuropsychiatr. 2018;30(2):70 [Crossref]
18- Mirjačić Martinović K, Vuletić A, Mališić E, Srdić-Rajić T, Tišma Miletić N, Babović N, Jurišić V. Increased circulating TGF-β1 is associated with impairment in NK cell effector functions in metastatic melanoma patients. Growth Factors. 2022;40(5-6):231 [Crossref]
19- E. EL-HOUSEINI M, S. ARAFAT M, M. EL-HUSSEINY A, M. KASEM I, M. KAMEL M, H. EL-HABASHY A, M. KHAFAGY M, M. RADWAN E, H. HELAL M, S. ABDELLATEIF M. Biological and molecular studies on specific immune cells treated with checkpoint inhibitors for the thera-personal approach of breast cancer patients (ex-vivo study). 2021;29(5):319 [Crossref]